NCT04441333 is a NA clinical trial of AspivixTM cervical vacuum tenaculum in IUD Insertion, sponsored by Aspivix SA.

Who is sponsoring NCT04441333?

NCT04441333 is sponsored by Aspivix SA.

What drugs are being tested in NCT04441333?

Interventions in NCT04441333: AspivixTM cervical vacuum tenaculum.

What condition does NCT04441333 study?

NCT04441333 studies IUD Insertion.

Is NCT04441333 still recruiting?

NCT04441333 is currently completed. Last updated 11 December 2020.

Last reviewed 2020-12-11 · How we verify

NCT04441333

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Usability, Safety and Efficacy of AspivixTM

Completed NA Last updated 11 December 2020

What this trial tests

NA trial testing AspivixTM cervical vacuum tenaculum in IUD Insertion in 13 participants. Completed in 2 December 2020.

Timeline

1 July 2020

Primary endpoint
2 December 2020

2 December 2020

Quick facts

Lead sponsor	Aspivix SA
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	13
Start date	1 July 2020
Primary completion	2 December 2020
Estimated completion	2 December 2020
Sites	1 location across Switzerland

Drugs / interventions tested

AspivixTM cervical vacuum tenaculum

Conditions studied

IUD Insertion — all drugs for IUD Insertion →

Sponsor

Aspivix SA

Who can join

18 and older, female only, with IUD Insertion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD). Currently, the available instruments are traumatic tenacula, which could cause pain and bleeding and therefore represent an obstacle for certain patients to pursue their medical follow-up. AspivixTM is a new device, which enables atraumatic traction of the cervix while respecting its specific semi-circular anatomic shape through a system powered by a vacuum chamber. The aim of our pilot study is to assess the usability, safety and efficacy of the device. Note: Study is made of 2 phases (pilot phase followed by a comparative phase). Details regarding comparative study is registered separately.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety and Efficacy of an Atraumatic Uterine Cervical Traction Device: A Pilot Study.
Legardeur H, Masiello-Fonjallaz G, Jacot-Guillarmod M, Mathevet P. · · 2021 · cited 3× · PMID 35004719 · DOI 10.3389/fmed.2021.742182

Verify or expand the search:

Other Aspivix SA trials

Trials by the same sponsor.

NCT04441281 — Usability, Safety and Efficacy of AspivixTM (Comparative Study) · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04441333 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aspivix SA
Last refreshed: 11 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04441333.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing